Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5790
Abstract: Approximately 40% patients of diffuse large B‐cell lymphoma (DLBCL) would develop disease recurrence/progression after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis. An effective strategy to prolong the survival… read more here.
Keywords: maintenance; cell lymphoma; lenalidomide maintenance; large cell ... See more keywords
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0948-0
Abstract: The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase… read more here.
Keywords: shdct asct; lenalidomide maintenance; multiple myeloma; relapse ... See more keywords
A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2069564
Abstract: ABSTRACT Introduction Recent advances in the diagnosis and management of multiple myeloma (MM) have improved patient outcomes. This progress in our understanding of MM has resulted in continuous suppressive therapy concepts, including induction, high dose… read more here.
Keywords: maintenance; review; therapy; maintenance therapy ... See more keywords
The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2032656
Abstract: ABSTRACT Introduction For patients with multiple myeloma who are eligible for high-dose melphalan therapy and autologous stem cell transplant (ASCT), the strategy of maintenance with low-dose lenalidomide therapy has become the current standard of care.… read more here.
Keywords: maintenance; therapy; maintenance therapy; lenalidomide maintenance ... See more keywords
B-Cell/Mixed Phenotype Acute Leukemia Following Lenalidomide Maintenance For Multiple Myeloma: A Study Of Two Cases
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqaa161.334
Abstract: The incidence of patients with multiple myeloma (MM) followed by hematologic malignancies as second primary malignancy is around 0.8 – 3.1%. The majority of cases are myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), however,… read more here.
Keywords: multiple myeloma; leukemia; lenalidomide maintenance; mixed phenotype ... See more keywords
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18600
Abstract: Lenalidomide is an effective maintenance agent for patients with myeloma, prolonging first remission and, in transplant eligible patients, improving overall survival (OS) compared to observation. The ‘Myeloma XI’ trial, for newly diagnosed patients, aimed to… read more here.
Keywords: addition; day; maintenance; vorinostat lenalidomide ... See more keywords
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18642
Abstract: Low baseline NK‐cell counts (NKCCs) in patients with diffuse large B‐cell lymphoma (DLBCL) are associated with a poor prognosis. The REMARC phase III trial (NCT01122472) showed that lenalidomide maintenance prolonged PFS in rituximab–chemotherapy responders. We… read more here.
Keywords: cell; prognosis; baseline; lenalidomide maintenance ... See more keywords
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of haematology"
DOI: 10.1111/bjh.18821
Abstract: Improved maintenance treatments are needed for patients with relapsed/refractory aggressive lymphomas after autologous haematopoietic stem cell transplantation (ASCT). Several studies with lenalidomide have been found to have activity in the treatment of relapsed/refractory aggressive lymphomas.… read more here.
Keywords: cell; lymphoma; maintenance; transplantation ... See more keywords
Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma Post Autologous Stem Cell Transplant: A Comparison of Real-World Treatment Outcomes and Costs
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.2189.2189
Abstract: BACKGROUND In 2017, lenalidomide maintenance therapy (R-MT) was approved for patients (pts) who received an up-front autologous hematopoietic stem cell transplantation (ASCT) in the United States (US) and Europe. The total cost of care for… read more here.
Keywords: lenalidomide maintenance; line; maintenance; treatment ... See more keywords
Maintenance Treatment with Lenalidomide for Multiple Myeloma Increases the Proportion of MRD Negative (Flow-/PET-CT-) Patients
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.3098.3098
Abstract: Introduction Lenalidomide maintenance therapy in Multiple Myeloma has been used in order to prolong the Progression-Free Survival (PFS) obtained with any induction therapy through the depletion of residual tumor burden. In this way, it is… read more here.
Keywords: lenalidomide maintenance; maintenance therapy; maintenance; multiple myeloma ... See more keywords
Lenalidomide Maintenance Therapy after Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Multiple Myeloma Patients: Factors That Impact Treatment
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.5416.5416
Abstract: Introduction Maintenance therapy after an Autologous PBSCT remains the standard of care in patients with Multiple Myeloma, having been shown to increase progression free survival, and based on the CALGB study, overall survival. Accordingly, Lenalidomide… read more here.
Keywords: lenalidomide maintenance; maintenance therapy; maintenance; autologous pbsct ... See more keywords